Subscribe to our Newsletters !!
Cell therapy is a medical breakthrough in addressi
Chromium, a transition metal with profound pharmac
Few names in the medical history have had a profou
We are pleased to announce that we have recently e
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of Mi
CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), today announced the commercial launch of its new PhysioMimix™ OOC Multi-Organ MPS.
The next-generation system unites CN Bio’s in vitro 3D liver model, whose phenotype and functions mimic that in vivo, with a range of other organs to more accurately recapitulate the multi-organ and systemic effects observed in humans. Demonstrating a crucial milestone in the provider’s mission to develop the most complete human’body-on-a-chip’ from the lab, the PhysioMimix OOC Multi-Organ MPS will offer advanced insights into the potential effects of novel therapeutics that were previously only achievable using animal models.
CN Bio’s Multi-Organ MPS enables researchers to generate sophisticated in vitro models that better reflect human inter-organ crosstalk effects when compared with single-organ MPS, or animal models. This system can be utilized to decrease the probability of clinical trial failures due to cross-species translational differences and may be utilised in the creation of new human-specific modalities for which animal models are unsuited.
The business’s advanced 3D liver model can be reliably and easily interconnected with other organs (such as gut, kidney or lung ) to supply a human in vitro alternative to animal or in silico first-pass metabolism studies (ADME), to elicit a deeper human-specific mechanistic understanding of disease states and to determine reactive metabolite-driven toxicity or multi-organ toxicity.
Furthermore, in vitro to in vivo, clinical predictions can be extrapolated using Physiologically-Based Pharmacokinetics (PBPK) mathematical models, to increase the accuracy and precision of data translation. For existing PhysioMimix users, an upgrade path is available.
The inherent biological differences of animal models with human physiology frequently result in the misrepresentation of pharmacological processes, contributing to the large proportion of new medicines that fail in clinical trials. Furthermore, in certain scenarios, animal models are unsuitable for efficacy and safety evaluation due to their genetic and immunological differences.
Our new multi-organ platform addresses the needs of a wider customer base, whilst providing the same ease-of-use, robustness, and reliability as the single-organ system which has been on the market since 2018. This launch extends CN Bio’s reach from world-leading provider of single-organ-on-a-chip technologies into multi-organ-on-a-chip, as we strive to expand the boundaries of humanized pre-clinical research and development.”
Dr David Hughes, CEO, CN Bio
CN Bio’s PhysioMimix Multi-Organ system will be introduced at the Society of Toxicology’s 2021 Virtual Annual Meeting and ToxExpo (exhibition booth 2155), 12th – 26th March 2021:
For more information, please visit: https://cn-bio.com/sot-2021/
For future details on the PhysioMimix OOC range, now comprising the PhysioMimix Single-Organ and PhysioMimix Multi-Organ Systems, please visit: https://cn-bio.com/physiomimixooc/
